The Technical Analyst
Anavex Life Sciences Corp [AVXL]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Anavex Life Sciences Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-6.63% $3.80
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 307.18 mill |
| EPS: | -0.640 |
| P/E: | -5.94 |
| Earnings Date: | Aug 08, 2023 |
| SharesOutstanding: | 80.84 mill |
| Avg Daily Volume: | 1.257 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.94 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.01x |
| Company: PE -5.94 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.893 (-50.19%) $-1.907 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.49 - 4.11 ( +/- 8.13%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-28 | Missling Christopher U | Buy | 73 380 | Common Stock |
| 2024-03-28 | Missling Christopher U | Sell | 73 380 | Common Stock |
| 2024-03-28 | Missling Christopher U | Sell | 73 380 | Stock Option (Right to Buy) |
| 2024-02-20 | Donhauser Peter D.o. | Buy | 50 000 | Stock Option (Right to Buy) |
| 2024-02-20 | Thomas Steffen | Buy | 50 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 3.73 |
| Last 100 transactions |
| Buy: 6 187 971 | Sell: 2 192 392 |
Forecast:
16:00 - $3.80
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.80
Forecast 2: 16:00 - $3.80
Forecast 3: 16:00 - $3.80
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.80 (-6.63% ) |
| Volume | 1.632 mill |
| Avg. Vol. | 1.257 mill |
| % of Avg. Vol | 129.87 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AVXL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $5.65 | N/A | Active |
|---|
AVXL
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Last 10 Buy Signals
Latest Press Releases
2024-04-18 22:00:00 - Press Release
Levi & Korsinsky Notifies Anavex Life Sciences Corporation Investors Of A Class Action Lawsuit And Upcoming Deadline - Avxl
New york, ny / accesswire / april 18, 2024 / if you suffered a loss on your anavex life sciences corporation (nasdaq:avxl) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=76188&wire=1 or contact joseph e. levi, esq.
2024-04-18 17:30:00 - Press Release
Lost Money On Anavex Life Sciences Corporation (avxl)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
New york, ny / accesswire / april 18, 2024 / if you suffered a loss on your anavex life sciences corporation (nasdaq:avxl) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=76157&wire=1 or contact joseph e. levi, esq.
2024-04-18 16:51:00 - Press Release
Avxl Investors Have Opportunity To Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit
Bensalem, pa. , april 18, 2024 /prnewswire/ -- law offices of howard g.
2024-04-18 13:45:00 - Press Release
Anavex Life Sciences Corporation Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 13, 2024 To Discuss Your Rights - Avxl
New york, ny / accesswire / april 18, 2024 / if you suffered a loss on your anavex life sciences corporation (nasdaq:avxl) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=76129&wire=1 or contact joseph e. levi, esq.
2024-04-18 13:45:00 - Press Release
Levi & Korsinsky Reminds Anavex Life Sciences Corporation Investors Of The Pending Class Action Lawsuit With A Lead Plaintiff Deadline Of May 13, 2024 - Avxl
New york, ny / accesswire / april 18, 2024 / if you suffered a loss on your anavex life sciences corporation (nasdaq:avxl) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=76132&wire=1 or contact joseph e. levi, esq.
Latest News
2024-04-11 07:30:00 - GlobeNewsWire
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the Noble Capital Markets Virtual Healthcare Equity Conference. Christopher U Missling, PhD, President & Chief Executive Officer is scheduled to present at 1:30pm ET, TRACK 2 on Thursday, April 18th, 2024.
2024-03-25 07:30:00 - GlobeNewsWire
Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference, April 8 – 11, 2024. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 8:45 AM (ET) on Monday, April 8th, 2024.
2024-02-26 07:30:00 - GlobeNewsWire
Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 44th Annual TD Cowen Health Care Conference, March 4-6, 2024. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled at 1:30 PM (ET) on Monday, March 4th, 2024, at the Boston Marriott Copley Place in Boston, MA.
2024-02-07 12:46:02 - Seeking Alpha
Anavex Life Sciences Corp. (AVXL) Q1 2024 Earnings Call Transcript
2024-02-01 07:30:00 - GlobeNewsWire
Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
Webcast and Conference Call To be Held Wednesday, February 7th, 2024, 8:30 am ET Webcast and Conference Call To be Held Wednesday, February 7th, 2024, 8:30 am ET
2024-01-31 13:16:05 - Zacks Investment Research
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.
2024-01-31 10:56:04 - Zacks Investment Research
Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 530.68%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 530.7% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-01-31 07:05:15 - Zacks Investment Research
New Strong Buy Stocks for January 31st
ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.
2024-01-26 07:26:04 - Zacks Investment Research
New Strong Buy Stocks for January 26th
IKT, EGO, MDB, PD and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.
2024-01-24 13:01:04 - Zacks Investment Research
Anavex Life Sciences (AVXL) Upgraded to Strong Buy: Here's Why
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.